No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Dec 25, 2025
On 25 December 2025, Innovent announced that its Tabosun® (ipilimumab N01 injection), referencing BMS’ Yervoy®, in combination with Tyvyt® (sintilimab, co-developed by Innovent and Eli Lilly), has been approved by China’s National Medical Products Administration as a neoadjuvant treatment for stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer.
Dec 25, 2025
On 22 December 2025, Amneal Pharmaceuticals and mAbxience announced that the FDA has approved Boncresa™ and Oziltus™ (MB09), biosimilars to Amgen’s Prolia® and Xgeva® (denosumab) respectively.
Dec 24, 2025
On 24 December 2025, Celltrion announced that it has secured approval in Korea for an autoinjector presentation (75mg and 150 mg) of Omlyclo, biosimilar to Novartis’ Xolair® (omalizumab).
Dec 23, 2025
On 23 December 2025, Samsung Bioepis announced that it has received marketing approval in Japan for Nipro™, biosimilar to J&J’s/Janssen’s Stelara® (ustekinumab).
Dec 23, 2025
On 23 December 2025, Formycon and Bioeq (a joint venture between Formycon and Polpharma Biologics) jointly announced that the FDA approved Nufymco® as an interchangeable biosimilar to Genentech’s Lucentis® (ranibizumab).
Dec 23, 2025
On 23 December 2025, CSPC Pharmaceutical Group Limited announced that it has obtained approval from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China of its Daratumumab Injection, biosimilar to Johnson & Johnson’s Darzalex®.
Dec 23, 2025
On 23 December 2025, Biocon Biologics announced that is has secured full and exclusive global rights for Hulio®, biosimilar to AbbVie’s Humira® (adalimumab), from Fujifilm Kyowa Kirin Biologics Co., Ltd. (FKB).
Dec 22, 2025
On 22 December 2025, Alvotech announced the European launch of Gobivaz® (AVT05), biosimilar to Janssen’s Simponi® (golimumab), which is the first golimumab biosimilar to be marketed worldwide.
Dec 22, 2025
On 22 December 2025, R-Pharm announced that it has presented its progress on two biosimilar products at the 29th Russian Oncology Congress: Persinthia®, biosimilar to Roche’s Perjeta® (pertuzumab), for the treatment of HER2-positive breast cancer; and Arcetux®, biosimilar to Eli Lilly/Merck KgGa’s Erbitux® (cetuximab), for treatment of head and neck tumours.
Dec 19, 2025
On 19 December 2025, Shanghai Henlius Biotech announced to investors that the US FDA has approved an investigational new drug application (IND) for the phase 1 clinical trial of HLX18, biosimilar to BMS’ Opdivo® (nivolumab), for the treatment of multiple solid tumours.
Dec 19, 2025
On 19 December 2025, Alvotech and Teva jointly announced that they have reached a settlement and licence agreement with Regeneron regarding the US launch of Alvotech’s AVT06, biosimilar to Regeneron’s Eylea® (aflibercept).
Dec 19, 2025
On 19 December 2025, Johnson & Johnson announced that the European Commission has approved an indication extension for Tremfya® (guselkumab) as a subcutaneous treatment to treat moderate to severe plaque psoriasis (Pso) in children and adolescents aged six and older who are candidates for systemic therapy.
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.